[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:nonalcoholic-fatty-liver-disease":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":312},"Nonalcoholic Fatty Liver Disease",68,49,[8,16,23,30,36,42,48,54,60,67,73,79,85,91,97,103,109,115,121,127,133,139,144,150,155,161,167,173,179,185,191,197,203,209,215,221,226,232,238,244,250,256,263,269,275,281,287,293,299,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07097506","Effect of Ketone Esters on Liver Fat Content and Metabolic Function",[12],"Phase 2","RECRUITING","2026-08-26T02:19:10.436356Z","2026-07-19T19:36:05.064106Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07553663","Evaluating the Pharmacokinetics and Safety of Miricorilant",[20],"Phase 1","2026-08-26T02:18:51.833592Z","2026-05-29T15:36:40.191799Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07165028","A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)",[27],"Phase 3","2026-08-26T02:15:10.362237Z","2026-05-05T02:43:29.671173Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06355310","Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease",[12],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:29.055600Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06133101","Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)",[12],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:28.963855Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05935826","Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)",[27],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:28.866721Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06477146","Milk Thistle Clinical Trial in Pediatric NAFLD",[12],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:28.841540Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04899102","Intermittent Fasting for NAFLD in Adults",[],"2026-08-26T02:17:11.311767Z","2026-05-05T02:43:28.837013Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT06836609","A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD\u002FMASH)",[64],"Phase 1\u002FPhase 2","2026-08-26T02:18:31.164304Z","2026-05-05T02:43:28.738012Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05648214","A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",[64],"2026-08-26T02:17:21.315591Z","2026-05-05T02:43:26.719386Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07143968","A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV",[12],"2026-08-26T02:17:57.117858Z","2026-04-29T02:57:57.163934Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial",[],"2026-08-26T02:16:29.226604Z","2026-07-05T05:32:16.744670Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07527910","A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD",[12],"2026-08-26T02:19:05.360997Z","2026-07-05T03:45:20.252831Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05526144","Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans",[12],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:29.659734Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07441252","A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight",[12],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:29.338203Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT07358546","A Study of Efimosfermin Alfa in Adults With Hepatic Impairment",[20],"2026-08-26T02:16:54.876240Z","2026-07-05T05:32:16.678763Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07465341","Michigan Weight Navigation Program (MiWeigh) Study",[],"2026-08-26T02:18:26.932189Z","2026-05-05T02:35:31.931704Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05424003","Randomized Double Blinded Placebo-Controlled w\u002FSemaglutide to Prevent Weight Gain After Liver Transplant",[12],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:29.387650Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT07298213","Corazones Unidos Study",[],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:27.414598Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT05332613","Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease",[],"2026-08-26T02:16:01.079019Z","2026-05-05T02:35:31.643823Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT05165706","Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance",[],"2026-08-26T02:18:17.950264Z","2026-05-05T02:43:26.756994Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":28,"content_modified":143},"NCT07270601","Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis",[],"2026-05-05T02:43:28.794129Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT07382349","A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease",[],"2026-08-26T02:16:26.411851Z","2026-05-05T02:43:28.359954Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":89,"content_modified":154},"NCT04365855","The Olmsted NAFLD Epidemiology Study (TONES)",[],"2026-05-05T02:43:28.349159Z",{"nct_id":156,"title":157,"phases":158,"status":13,"updated_at":159,"content_modified":160},"NCT07192159","Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD",[],"2026-08-26T02:16:01.910993Z","2026-05-05T02:43:26.688932Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":165,"content_modified":166},"NCT07518784","Accurate Point of Care Liver Disease Diagnostics (Phase 2)",[],"2026-08-26T02:18:12.612955Z","2026-05-13T02:55:06.712357Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT07321925","Thermoacoustic Method for Estimating Liver Fat Fraction",[],"2026-08-26T02:16:06.684983Z","2026-05-13T02:55:06.687654Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":177,"content_modified":178},"NCT07090083","Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease and Food Insecurity",[],"2026-08-26T02:17:10.213717Z","2026-05-13T02:55:06.653509Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":183,"content_modified":184},"NCT06706856","Quantitative Ultrasound to Assess Steatotic Liver Disease in Children",[],"2026-08-26T02:15:46.655893Z","2026-05-13T02:55:06.564288Z",{"nct_id":186,"title":187,"phases":188,"status":13,"updated_at":189,"content_modified":190},"NCT04807868","AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)",[],"2026-08-26T02:16:22.235886Z","2026-05-13T02:55:06.270862Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT04634643","Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)",[],"2026-08-26T02:19:27.519777Z","2026-05-13T02:55:06.257073Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT06592820","Endoscopic Ultrasound Shear Wave Elastography Study",[],"2026-08-26T02:19:01.741747Z","2026-05-13T02:55:06.552998Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT06571474","Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)",[],"2026-08-26T02:18:40.612983Z","2026-05-13T02:55:06.549147Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT06124261","Androgens and NAFLD Longitudinal Cohort Study",[],"2026-08-26T02:15:51.395565Z","2026-05-13T02:55:06.416984Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":219,"content_modified":220},"NCT05728697","Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease",[],"2026-08-26T02:16:16.169331Z","2026-05-13T02:55:06.372763Z",{"nct_id":222,"title":223,"phases":224,"status":13,"updated_at":77,"content_modified":225},"NCT05463796","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer",[],"2026-05-13T02:55:06.364704Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":177,"content_modified":231},"NCT06934642","Effect of Tirzepatide on Markers of MASLD in Patients With Obesity",[230],"Early Phase 1","2026-05-05T02:43:29.131236Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT06453915","NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease",[230],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.989461Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT06671886","NAFLD Clinical Care Pathway",[],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:28.650499Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":248,"content_modified":249},"NCT02193295","Reversal of Lipid-Induced Insulin Resistance",[],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.299237Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":254,"content_modified":255},"NCT07091539","Food Insecurity and MASLD: A Fruit and Vegetable Intervention Study",[],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:27.401636Z",{"nct_id":257,"title":258,"phases":259,"status":13,"updated_at":261,"content_modified":262},"NCT05305287","Quantifying Hepatic Mitochondrial Fluxes in Humans",[260],"Phase 4","2026-08-26T02:17:42.501124Z","2026-05-05T02:43:27.255189Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT03884075","Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)",[12],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:27.249997Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT07159386","Advanced Fibrosis Detection for MASLD in Primary Care",[],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:28.415965Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT06354088","Human Models of Selective Insulin Resistance: Alpelisib, Part I",[20],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:27.181472Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":285,"content_modified":286},"NCT06335771","Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity",[],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:27.107153Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":291,"content_modified":292},"NCT06824974","Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer",[],"2026-08-26T02:16:20.336282Z","2026-07-05T05:32:16.696638Z",{"nct_id":294,"title":295,"phases":296,"status":13,"updated_at":297,"content_modified":298},"NCT07403604","Effect of Insulin Lowering on Lipogenesis",[20],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:29.663624Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":303,"content_modified":304},"NCT06661538","Implementing Food Referrals for Equity and Sustained Health",[12],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:28.727228Z",{"nct_id":306,"title":307,"phases":308,"status":309,"updated_at":248,"content_modified":310},"NCT03867487","SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease",[12],"NOT_YET_RECRUITING","2026-05-05T02:35:31.729130Z",[],[313,317,321,325,329,332,335,339,342,346,349,352,355,359,362,365,368,371],{"state":314,"count":315,"slug":316},"California",18,"california",{"state":318,"count":319,"slug":320},"Texas",11,"texas",{"state":322,"count":323,"slug":324},"New York",8,"new-york",{"state":326,"count":327,"slug":328},"Florida",7,"florida",{"state":330,"count":327,"slug":331},"Massachusetts","massachusetts",{"state":333,"count":327,"slug":334},"Missouri","missouri",{"state":336,"count":337,"slug":338},"Illinois",5,"illinois",{"state":340,"count":337,"slug":341},"Maryland","maryland",{"state":343,"count":344,"slug":345},"Arizona",4,"arizona",{"state":347,"count":344,"slug":348},"Louisiana","louisiana",{"state":350,"count":344,"slug":351},"Ohio","ohio",{"state":353,"count":344,"slug":354},"Tennessee","tennessee",{"state":356,"count":357,"slug":358},"Alabama",3,"alabama",{"state":360,"count":357,"slug":361},"Connecticut","connecticut",{"state":363,"count":357,"slug":364},"Michigan","michigan",{"state":366,"count":357,"slug":367},"North Carolina","north-carolina",{"state":369,"count":357,"slug":370},"South Carolina","south-carolina",{"state":372,"count":357,"slug":373},"Virginia","virginia"]